Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
19 results
D2.332 - First reported case of IgE-mediated food allergy to Tetragonia tetragonioides (New Zealand spinach)
D2.337 - REMA Score Outperforms C-kit and Tryptase in Identifying Mast Cell Disorders in Hymenoptera Venom Allergy
D2.347 - Filaggrin Mutation in a Patient with Ant Anaphylaxis: Case Report and Literature Review
D2.333 - Glatiramer acetate: when immunomodulation is not enough
D2.335 - Single-nucleotide polymorphisms in the Mas-related G protein-coupled receptor X2 alter in vitro cellular responses to specific drugs
D2.336 - Risk of systemic reactions among school-age children sensitized to fish, crustaceans and molluscs
D2.338 - Gaps in Adrenaline Autoinjector Education Among Patients at Risk of Anaphylaxis: A Cross-Sectional Study
D2.340 - Improving Post-Anaphylaxis Referral Pathways in the Emergency Department: A Quality Improvement Initiative
D2.341 - Comparative Evaluation of Diagnostic Criteria for Food Allergy–Induced Anaphylaxis: Accuracy, Clinical Applicability, and Validation
D2.342 - Environmental Exposure Predicts Severity of Hymenoptera Venom Anaphylaxis Better Than Classical Biomarkers: Added Value of Component-Resolved Diagnostics
D2.343 - Anaphylactic Reaction to Methylprednisolone Acetate in a Young Adult
D2.344 - National Data on Anaphylaxis in Brazil: Findings from the Brazilian Registry
D2.345 - Successful Desensitization in a Pediatric Patient Who Developed an Immediate-Type Systemic Hypersensitivity Reaction to FVIII/vWF Concentrate
D2.346 - When cold triggers anaphylaxis
- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study
- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib
- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series
- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis
Download the app
The congress at your fingertips
Available on
Download